FDA Approves a First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer: Daraxonrasib
The FDA has approved a first-in-class RAS inhibitor for metastatic pancreatic adenocarcinoma, the most common form of pancreatic cancer. Taken as a once-daily pill, Rasonque (daraxonrasib) nearly doubled median overall survival compared with standard chemotherapy in the clinical trial.
August 26, 2026 — The U.S. Food and Drug Administration (FDA) announced the approval of Rasonque (daraxonrasib), a first-in-class RAS inhibitor developed for the treatment of metastatic pancreatic adenocarcinoma, the most common form of pancreatic cancer. Arriving months ahead of the expected date, this approval offers a critical new option for patients with a disease that has historically been extremely difficult to treat.
Targeting the RAS Proteins That Drive Tumor Growth
Pancreatic adenocarcinoma, which arises from the cells lining the pancreatic ducts, accounts for roughly 90% to 95% of the 67,000 new pancreatic cancer cases diagnosed each year in the United States. Daraxonrasib is a targeted small molecule, taken once daily as a pill, that directly targets multiple forms of the RAS protein, the principal driver of tumor growth in the large majority of pancreatic cancer patients.
The scope of the approval is defined as follows:
- Patient group: Adults diagnosed with metastatic pancreatic adenocarcinoma.
- Prior therapy requirement: Having received at least one prior line of systemic therapy (chemotherapy and similar).
- Alternative criterion: Patients who are not eligible for multi-agent systemic therapy are also covered by the approval.
- Administration: A once-daily oral pill.
Overall Survival Doubled
The FDA approval is based on the striking results of a randomized, open-label, multicenter clinical trial that enrolled 500 previously treated adults with metastatic pancreatic adenocarcinoma.
| Treatment Arm | Median Overall Survival |
|---|---|
| Standard chemotherapy | 6.7 months |
| Daraxonrasib (Rasonque) | 13.2 months |
According to the trial data, median overall survival was 6.7 months in patients receiving standard chemotherapy, while it rose to 13.2 months in patients treated with daraxonrasib, providing a clear survival advantage.
Approval Granted 6.5 Months Early
Pancreatic cancer accounts for a disproportionately high share of cancer deaths, largely because it is usually diagnosed late, follows an aggressive course and offers limited treatment options. Given the urgency of bringing innovative therapies to cancer patients, the FDA granted the approval a full 6.5 months ahead of the scheduled date.
💬 What the FDA Says
Dr. Angelo de Claro, Director of the FDA Oncology Center of Excellence, stated that the drug demonstrated unprecedented results in an area of high unmet medical need.
The drug was also granted Breakthrough Therapy and Orphan Drug designations by the FDA, and was reviewed under the Priority Review program.
Safety Profile
The most common adverse reactions associated with daraxonrasib in clinical trials were:
- Skin rash
- Diarrhea
- Inflammation of the oral mucosa (stomatitis)
- Nausea and vomiting
- Fatigue
- Abdominal pain
- Edema
- Decreased appetite
- Bleeding
Conclusion
In metastatic pancreatic cancer, where treatment options have for many years been largely limited to chemotherapy, the approval of the first drug to directly target RAS, the principal driver of the tumor, marks an important turning point. Doubling overall survival shows that the targeted, precision medicine approach can deliver results even in the most difficult cancer types.